Skip to main content
Top
Published in:

Open Access 09-05-2024 | Dupilumab | Rhinology

Diagnostics of allergic rhinitis under dupilumab therapy

Authors: Patrick Huber, Moritz Gröger, Clemens Stihl, Hanna Frankenberger, Mattis Bertlich, Frank Haubner, Donata Gellrich

Published in: European Archives of Oto-Rhino-Laryngology | Issue 8/2024

Login to get access

Abstract

Background

Allergic rhinits is a prevalent condition, affecting a substantial proportion of the population. This study investigates the impact of ongoing biologic therapy, specifically with Dupilumab, on allergy diagnostics in patients with allergic rhinits.

Methods

Various tests, including the Skin Prick Test, serum IgE levels and Allergy Screening Panels, were examined for their effectiveness in detecting sensitizations during biologic treatment.

Results

The results indicate a significant decline in total IgE levels following biologic therapy initiation, aligning with previous findings on Dupilumab's inhibitory effects on IL-4 and IL-13. However, the specific IgE to total IgE ratio for major allergens was not significantly reduced. Comparing diagnostic tools, the Skin Prick Test demonstrates an impressive retention rate of sensitizations (98%) during Dupilumab treatment, outperforming the Allergy Screening Panel, which shows a 75% detection rate. Notably, the panel displays limitations in capturing lower sensitization levels.

Conclusion

In summary, this study underscores that, despite the influence of biologic therapy on certain markers, standard allergy tests remain viable while emphasizing the importance of considering specific IgE levels rather than relying solely on CAP classes. The Skin Prick Test in particular proves to be a reliable tool for identifying sensitizations during Dupilumab treatment. The results offer valuable guidance for the diagnostic management of Allergic rhinits in individuals subjected to Dupilumab treatment.
Literature
1.
go back to reference Meltzer EO (2016) Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am 36(2):235–248CrossRefPubMed Meltzer EO (2016) Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am 36(2):235–248CrossRefPubMed
2.
go back to reference Greiner AN, Hellings PW, Rotiroti G, Scadding GK (2011) Allergic rhinitis. Lancet 378(9809):2112–2122CrossRefPubMed Greiner AN, Hellings PW, Rotiroti G, Scadding GK (2011) Allergic rhinitis. Lancet 378(9809):2112–2122CrossRefPubMed
3.
go back to reference Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC (2007) A survey of the burden of allergic rhinitis in Europe. Allergy 62(Suppl 85):17–25CrossRefPubMed Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC (2007) A survey of the burden of allergic rhinitis in Europe. Allergy 62(Suppl 85):17–25CrossRefPubMed
4.
go back to reference Kato A, Schleimer RP (2007) Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 19(6):711–720CrossRefPubMedPubMedCentral Kato A, Schleimer RP (2007) Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 19(6):711–720CrossRefPubMedPubMedCentral
5.
go back to reference Bernstein DI, Schwartz G, Bernstein JA (2016) Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am 36(2):261–278CrossRefPubMed Bernstein DI, Schwartz G, Bernstein JA (2016) Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am 36(2):261–278CrossRefPubMed
6.
go back to reference Luengo O, Labrador-Horrillo M (2022) Molecular Allergy Diagnosis in Clinical Practice: Frequently Asked Questions. J Investig Allergol Clin Immunol 32(1):1–12CrossRefPubMed Luengo O, Labrador-Horrillo M (2022) Molecular Allergy Diagnosis in Clinical Practice: Frequently Asked Questions. J Investig Allergol Clin Immunol 32(1):1–12CrossRefPubMed
7.
go back to reference Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.
8.
go back to reference Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract 9(3):1133–1141CrossRefPubMed Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract 9(3):1133–1141CrossRefPubMed
11.
go back to reference Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK et al (2016) Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 9(1):33CrossRefPubMedPubMedCentral Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK et al (2016) Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 9(1):33CrossRefPubMedPubMedCentral
12.
go back to reference van der Lans RJL, Otten JJ, Adriaensen G, Hoven DR, Benoist LB, Fokkens WJ, Reitsma S (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78(10):2684–2697CrossRefPubMed van der Lans RJL, Otten JJ, Adriaensen G, Hoven DR, Benoist LB, Fokkens WJ, Reitsma S (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78(10):2684–2697CrossRefPubMed
13.
go back to reference De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). Allergy 78(10):2669–2683CrossRefPubMed De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). Allergy 78(10):2669–2683CrossRefPubMed
14.
go back to reference Iordache A, Balica NC, Horhat ID, Morar R, Tischer AA, Milcu AI et al (2022) Allergic rhinitis associated with nasal polyps and rhinosinusitis - histopathological and immunohistochemical study. Rom J Morphol Embryol 63(2):413–419CrossRefPubMedPubMedCentral Iordache A, Balica NC, Horhat ID, Morar R, Tischer AA, Milcu AI et al (2022) Allergic rhinitis associated with nasal polyps and rhinosinusitis - histopathological and immunohistochemical study. Rom J Morphol Embryol 63(2):413–419CrossRefPubMedPubMedCentral
15.
go back to reference Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD et al (2020) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev 9(6):742–755CrossRefPubMedPubMedCentral Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD et al (2020) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev 9(6):742–755CrossRefPubMedPubMedCentral
16.
go back to reference Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638–1650CrossRefPubMed Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638–1650CrossRefPubMed
17.
go back to reference Spekhorst LS, van der Rijst LP, de Graaf M, van Megen M, Zuithoff NPA, Knulst AC et al (2023) Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 78(3):875–878CrossRefPubMed Spekhorst LS, van der Rijst LP, de Graaf M, van Megen M, Zuithoff NPA, Knulst AC et al (2023) Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 78(3):875–878CrossRefPubMed
18.
go back to reference Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S et al (2023) International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol 13(4):293–859CrossRefPubMed Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S et al (2023) International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol 13(4):293–859CrossRefPubMed
Metadata
Title
Diagnostics of allergic rhinitis under dupilumab therapy
Authors
Patrick Huber
Moritz Gröger
Clemens Stihl
Hanna Frankenberger
Mattis Bertlich
Frank Haubner
Donata Gellrich
Publication date
09-05-2024
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 8/2024
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-024-08700-2